Karyopharm Therapeutics Inc. (KPTI) earnings
KPTI earnings moved a median of -4.86% by the close. Quarterly and annual KPTI reports and results, each read against the price at its own news timestamp. Back to the KPTI overview →
30 measured KPTI earnings events.
Where these KPTI earnings landedvs 29 measured KPTI earnings reactions
| Middle 50% of KPTI earnings reactions | -7.08% to -2.28% |
|---|---|
| Median reaction (to close) | -4.86% |
| Measured reactions | 29 |
Point-in-time · zero look-ahead
Half of the 29 KPTI earnings events with a measured close landed between -7.08% and -2.28%; 21% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Form 10-Q Karyopharm Therapeutics For: Jun 30 | SEC filing · Form 10-Q | +0.80% | -3.87% | |
| Karyopharm Reports Second Quarter 2026 Financial Results and Highlights Continued Progress Toward Myelofibrosis sNDA Submission | Press release | +0.80% | -3.87% | |
| Karyopharm to Report Second Quarter 2026 Financial Results on August 13, 2026 | Press release | +1.22% | — | |
| Form 10-Q Karyopharm Therapeutics For: Mar 31 | SEC filing · Form 10-Q | +5.58% | -6.32% | |
| Karyopharm Reports First Quarter 2026 Financial Results and Completion of Phase 3 Endometrial Cancer Trial Enrollment | Press release | +5.58% | -6.32% | |
| Karyopharm to Report First Quarter 2026 Financial Results on May 14, 2026 | Press release | +0.00% | -1.23% | |
| Form 10-K Karyopharm Therapeutics For: Dec 31 | SEC filing · Form 10-K | +0.45% | -4.45% | |
| Form 10-Q Karyopharm Therapeutics For: Sep 30 | SEC filing · Form 10-Q | +1.55% | +4.66% | |
| Karyopharm Reports Third Quarter 2025 Financial Results and Highlights Recent Company Progress | Press release | +1.55% | +4.66% | |
| Karyopharm to Report Third Quarter 2025 Financial Results on November 3, 2025 | Press release | -3.00% | +1.26% | |
| Form 10-Q Karyopharm Therapeutics For: Jun 30 | SEC filing · Form 10-Q | -5.78% | -5.75% | |
| Karyopharm Reports Second Quarter 2025 Financial Results and Highlights Recent Company Progress | Press release | -5.78% | -5.75% | |
| Karyopharm to Report Second Quarter 2025 Financial Results on August 11, 2025 | Press release | +0.75% | -2.76% | |
| Form 10-Q Karyopharm Therapeutics For: Mar 31 | SEC filing · Form 10-Q | -1.30% | -14.44% | |
| Karyopharm Reports First Quarter 2025 Financial Results and Announces New Data in Myelofibrosis that Further Suggests Selinexor May Lead to Meaningful Spleen Volume Reduction, Symptom Improvement, Hemoglobin Stabilization and Disease Modification | Press release | -1.30% | -14.44% | |
| Karyopharm to Report First Quarter 2025 Financial Results on May 12, 2025 | Press release | +6.10% | -2.28% | |
| Form 10-K Karyopharm Therapeutics For: Dec 31 | SEC filing · Form 10-K | -14.03% | -2.69% | |
| Form 10-Q Karyopharm Therapeutics For: Sep 30 | SEC filing · Form 10-Q | +2.45% | -7.08% | |
| Karyopharm Reports Third Quarter 2024 Financial Results and Highlights Recent Company Progress | Press release | +2.45% | -7.08% | |
| Karyopharm to Report Third Quarter 2024 Financial Results on November 5, 2024 | Press release | -2.21% | +9.98% | |
| Form 10-Q Karyopharm Therapeutics For: Jun 30 | SEC filing · Form 10-Q | +1.09% | -9.67% | |
| Karyopharm Reports Second Quarter 2024 Financial Results and Highlights Recent Company Progress | Press release | +1.09% | -9.67% | |
| Karyopharm to Report Second Quarter 2024 Financial Results on August 6, 2024 | Press release | +1.88% | -5.83% | |
| Form 10-Q Karyopharm Therapeutics For: Mar 31 | SEC filing · Form 10-Q | -0.96% | +2.88% | |
| Karyopharm Reports First Quarter 2024 Financial Results and Highlights Recent Company Progress | Press release | -0.85% | -9.73% | |
| Karyopharm to Report First Quarter 2024 Financial Results on May 8, 2024 | Press release | +5.41% | +1.80% | |
| Form 10-K Karyopharm Therapeutics For: Dec 31 | SEC filing · Form 10-K | -4.17% | -12.78% | |
| Form 10-Q Karyopharm Therapeutics For: Sep 30 | SEC filing · Form 10-Q | +2.46% | -4.86% | |
| Karyopharm Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress | Press release | +2.46% | -4.86% | |
| Karyopharm to Report Third Quarter 2023 Financial Results on November 2, 2023 | Press release | +2.70% | -3.47% |
Keep exploring
More KPTI: analyst actions → · SEC filings → · KPTI overview →
Other Healthcare names and their earnings
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| ACADIA Pharmaceuticals Inc. (ACAD) | 392 | -0.14% | 43% |
| BioXcel Therapeutics, Inc. (BTAI) | 392 | -0.75% | 41% |
| Rubius Therapeutics, Inc. (RUBY) | 392 | -0.32% | 45% |
| Arrowhead Pharmaceuticals, Inc. (ARWR) | 391 | +0.13% | 52% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its earnings — that is what the link opens.